Trendlines’ shares in BioSight were acquired by Arkin Bio Ventures Ltd. in June 2017.
BioSight develops advanced therapeutics to enable safe and effective treatment for life-threatening diseases and to improve the quality of life for patients with cancer and related diseases.
BioSight’s pipeline of targeted chemotherapy pro-drugs target cancer cells and release active chemotherapy drugs inside the cancer cells while significantly minimizing the toxicity associated with conventional chemotherapy treatments.
Astarabine™, the company’s lead proprietary product is in clinical stages for the treatment of leukemia.
Endoscopic ultrasound fine needle biopsy
Portable, automatic system for peritoneal dialysis
Device for treating ischemic stroke
Anastomotic closure device for laparoscopic bowel resection
Miniature screwless spine fusion implant